Managing Benzodiazepine Prescriptions After Overdose

Risk Assessment and Management

The American Medical Association recommends that benzodiazepines should not be prescribed to patients with a history of benzodiazepine overdose, particularly when substance use disorder or concurrent opioid use is present, as the risks of fatal respiratory depression and repeat overdose far outweigh any potential benefits 1, 2
Patients with a history of substance use disorder are at near-absolute contraindication to benzodiazepine prescribing, as abuse and misuse commonly involve concomitant use of other medications, alcohol, and illicit substances, which is associated with increased frequency of serious adverse outcomes including death 2
Concurrent opioid use with benzodiazepines causes a near quadrupling of overdose death risk compared to opioids alone, making co-prescription extremely dangerous 1
The Centers for Disease Control and Prevention recommends that patients with prior overdose history are at markedly increased risk for repeat overdose and should not receive benzodiazepines 2

The American College of Physicians recommends that in most cases, benzodiazepines should be discontinued entirely after an overdose event, and a gradual taper rather than abrupt discontinuation should be initiated in patients on chronic benzodiazepines to avoid life-threatening withdrawal 1, 2
A slow taper schedule, reducing the benzodiazepine dose by 25% every 2-4 weeks, or even slower (10% per month) for patients on long-term therapy, is recommended 1

The National Institute on Drug Abuse recommends that if benzodiazepines must be continued in exceptional circumstances, critical safety measures should be implemented, including reviewing PDMP data before every prescription, prescribing naloxone, avoiding all concurrent CNS depressants, and arranging addiction treatment referral 1, 2
The Substance Abuse and Mental Health Services Administration recommends that patients with overdose history likely have substance use disorder requiring specialized treatment, and discontinuing care based on overdose history can worsen outcomes and constitutes patient abandonment 1, 2

The FDA recommends that flumazenil should not be used for chronic management of benzodiazepine dependence, as it is only for acute overdose reversal and precipitates dangerous withdrawal in dependent patients 3

The American Academy of Sleep Medicine suggests tapering clonazepam by 0.25 mg per week after reaching 1 mg/day, or by 0.5 mg every 2 weeks at higher doses, to avoid withdrawal while transitioning to safer alternatives 4
Even slower tapers (10% dose reduction per month) may be needed for patients on long-term therapy, according to the Mayo Clinic Proceedings 4
The goal of tapering is to avoid withdrawal while transitioning to safer alternatives such as cognitive-behavioral therapy, SSRIs for anxiety, or non-benzodiazepine treatments, as recommended by the Journal of Clinical Sleep Medicine and the Mayo Clinic Proceedings 4, 5

Elderly patients on clonazepam require extra caution due to slower metabolism and increased sensitivity to sedating effects, as noted by the Journal of Clinical Sleep Medicine 6
Older adults are more prone to falls, cognitive impairment, and postural instability, and may require more aggressive tapering plans for long-term use, according to the Journal of Clinical Sleep Medicine and the Mayo Clinic Proceedings 4, 6